BioSymetrics

BioSymetrics is a phenomics-driven drug discovery company founded in 2015, with a primary focus on integrating clinical and experimental data using machine learning to advance precision medicines. The company has collaborated with renowned healthcare and life science entities, including Northwell Health, Janssen, Sema4, and Mt. Sinai, to enhance disease understanding and expedite drug development. Their proprietary machine learning technology, Contingent-AI™, effectively detects and corrects biases during data preprocessing and identifies additional feature sets for analysis, thereby optimizing drug discovery processes. BioSymetrics stands out for its unique approach that combines in silico and in vivo techniques to deliver faster and more accurate predictive results for drug discovery research, reflecting an innovative and progressive mode of operation. The company, headquartered in the United States, operates as a remote-first organization, with teams based in Toronto and Boston. Having secured Seed Round investment in 01 January 2017 from AJI Capital, the company continues to actively hire as it carves its path in the fields of Artificial Intelligence, Machine Learning, Biotech, Healthcare, Data Analytics, Precision Medicine, Pharma, Life Sciences, Genomics, Digital Health, and MedTech. For more information, visit their website at www.biosymetrics.com.